Pharma BD Deal Intelligence
The Nasdaq listing was the real prize; both OncoMed oncology assets (etigilimab, navicixizumab) fizzled and were out-licensed for token sums, while Mereo's value now rests entirely on unrelated rare-disease assets.
Full analysis, sources & comparables →Endpoints framed the deal as Mereo executing a 'back flip onto Nasdaq' by combining with a 'flailing OncoMed,' highlighting the transaction as a low-cost route…
Post-close coverage emphasized Mereo retained 'a select number of OncoMed employees' and the Redwood City base, with skepticism about whether the navicixizumab…
Mereo announced FDA Fast Track designation for navicixizumab in heavily pretreated ovarian cancer following phase 1b data showing 43% ORR with paclitaxel — the…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
UK-listed Mereo BioPharma announced December 2018 stock-for-stock reverse merger with US-listed OncoMed Pharmaceuticals to gain Nasdaq listing and add two oncology candidates (navicixizumab anti-DLL4/VEGF bispecific and etigilimab anti-TIGIT). OncoMed shareholders received Mereo ADSs plus contingent value rights, with former OncoMed holders owning ~25% of combined company. Strategically notable as a precedent-setting transatlantic biotech reverse merger structure. Closed April 23, 2019.
The Nasdaq listing was the real prize; both OncoMed oncology assets (etigilimab, navicixizumab) fizzled and were out-licensed for token sums, while Mereo's value now rests entirely on unrelated rare-disease assets.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mereo BioPharma Group plc / OncoMed Pharmaceuticals, Inc. (this deal) | 2018 | $57M | 27 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2018 deals · Oncology deals